|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US5834266A
(en)
|
1993-02-12 |
1998-11-10 |
President & Fellows Of Harvard College |
Regulated apoptosis
|
|
US5830462A
(en)
|
1993-02-12 |
1998-11-03 |
President & Fellows Of Harvard College |
Regulated transcription of targeted genes and other biological events
|
|
US5869337A
(en)
|
1993-02-12 |
1999-02-09 |
President And Fellows Of Harvard College |
Regulated transcription of targeted genes and other biological events
|
|
ES2162863T3
(es)
|
1993-04-29 |
2002-01-16 |
Unilever Nv |
Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
|
|
US20030036654A1
(en)
|
1994-08-18 |
2003-02-20 |
Holt Dennis A. |
Synthetic multimerizing agents
|
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
|
DK1034298T3
(da)
|
1997-12-05 |
2012-01-30 |
Scripps Research Inst |
Humanisering af murint antistof
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
CA2430013C
(en)
|
2000-11-30 |
2011-11-22 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
EP1740615B1
(en)
|
2004-03-31 |
2014-11-05 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
WO2007137300A2
(en)
|
2006-05-23 |
2007-11-29 |
Bellicum Pharmaceuticals, Inc. |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
|
CA2815181C
(en)
|
2010-10-27 |
2020-09-15 |
William Gleason Richards |
Dkk1 antibodies and methods of use
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
AU2012209103B2
(en)
|
2011-01-26 |
2015-12-03 |
Takeda Pharmaceutical Company Limited |
Methods and compositions for the synthesis of multimerizing agents
|
|
US9987308B2
(en)
|
2011-03-23 |
2018-06-05 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
BR112014020826A8
(pt)
|
2012-02-24 |
2017-09-19 |
Stem Centrx Inc |
Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
|
|
GB201206559D0
(en)
|
2012-04-13 |
2012-05-30 |
Ucl Business Plc |
Polypeptide
|
|
DK2956175T3
(da)
|
2013-02-15 |
2017-11-27 |
Univ California |
Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
|
|
CA2905352A1
(en)
|
2013-03-14 |
2014-09-25 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling t cell proliferation
|
|
EP3925618A1
(en)
|
2013-07-29 |
2021-12-22 |
2seventy bio, Inc. |
Multipartite signaling proteins and uses thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
AU2015214145A1
(en)
|
2014-02-04 |
2016-08-25 |
Kite Pharma. Inc. |
Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
|
|
US10934346B2
(en)
|
2014-02-14 |
2021-03-02 |
Bellicum Pharmaceuticals, Inc. |
Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
|
|
CA2939941A1
(en)
|
2014-02-21 |
2015-08-27 |
Abbvie Stemcentrx Llc |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
BR112017013981A2
(pt)
|
2015-01-26 |
2018-01-02 |
Cellectis |
receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
MA41613A
(fr)
*
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
|
WO2016179319A1
(en)
|
2015-05-04 |
2016-11-10 |
Cellerant Therapeutics, Inc. |
Chimeric antigen receptors with ctla4 signal transduction domains
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
MX2018002166A
(es)
|
2015-08-20 |
2018-09-12 |
Abbvie Stemcentrx Llc |
Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
|
|
EP3356415B1
(en)
*
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr inhibitors for reduzing cholesterol levels
|
|
KR20230148844A
(ko)
|
2016-03-29 |
2023-10-25 |
유니버시티 오브 써던 캘리포니아 |
암을 표적하는 키메라 항원 수용체
|
|
CA3019650C
(en)
|
2016-04-01 |
2023-07-25 |
Kite Pharma, Inc. |
Chimeric receptors and methods of use thereof
|
|
US11261250B2
(en)
|
2016-07-22 |
2022-03-01 |
Fred Hutchinson Cancer Research Center |
Bi-specific molecule for cell-specific Notch inhibition and related methods and compositions
|
|
WO2018073394A1
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
|
WO2018151841A1
(en)
*
|
2017-02-17 |
2018-08-23 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
|
SG11201908980PA
(en)
|
2017-04-03 |
2019-10-30 |
Kite Pharma Inc |
Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
|
|
CN110536700A
(zh)
|
2017-04-19 |
2019-12-03 |
南加利福尼亚大学 |
用于治疗癌症的组合物和方法
|
|
PH12021551720A1
(en)
|
2019-03-01 |
2022-03-28 |
Allogene Therapeutics Inc |
Dll3 targeting chimeric antigen receptors and binding agents
|